An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : doxorubicin hydrochloride
  • drug : cyclophosphamide
  • drug : cytarabine
  • drug : daunorubicin hydrochloride
  • drug : dexamethasone
  • drug : vincristine sulfate
  • drug : mercaptopurine
  • drug : methotrexate
  • drug : pegaspargase
  • drug : thioguanine
  • radiation : radiation therapy

Phase: Phase 2

Eligibility

Ages Eligible For Study:

16 Years - 39 Years

External Links

Explore related trials

Contact information

Primary Contact:

Joselene Sipin-Sayno 6507368113

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: